New pill aims to stop flare-ups in rare nerve disease
NCT ID NCT05356858
First seen May 07, 2026 · Last updated Jun 16, 2026 · Updated 3 times
Summary
This study tested a daily pill called zanubrutinib in 6 adults with neuromyelitis optica spectrum disorder (NMOSD), a rare disease where the immune system attacks the optic nerves and spinal cord. The goal was to see if the drug could prevent relapses and reduce disability over 48 weeks. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
XuanWu Hospital
Beijing, Beijing Municipality, 100053, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.